meixatech
7 minutes ago
"RespireRx has developed a series of benzamide AMPA receptor-positive allosteric modulators, including CX546 and CX717, which have entered clinical phase II for the treatment of neurological disorders such as Alzheimer’s disease, attention deficit hyperactivity disorder, and cognitive dysfunction."